Neuronascent (NNI) discovers and develops therapies for depression, Down syndrome, Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Our lead compound for each indication have shown great promise in several cell culture and  disease models and show no sign of toxicity or other harmful effects.   These small-molecule, therapeutic, candidates all promote proliferation and new neurons from the brain’s own neural stem/progenitor cell populations. Preclinical studies of these candidates are currently under way, in-house and through contract laboratories, to determine if they could be tested in humans.

Each NNI therapeutic candidate is uniquely optimized to increase neuron numbers in the brain, to improve critical function and to diminish loss of neurons due to disease progression.  This ensures that each therapy targets a specific disease indication(s).

NEWS & EVENTS

Oct 20, 2011 - Neuronascent Issued US Patent for Neurogenesis, Therapeutic Candidates - Read more...

June 27 - 30, 2011 - Dr. Kelleher-Andersson, the President and CSO of Neuronascent, is planning to attend the BIO meeting in Washington D.C. This BIO International meeting “is the largest global event for the biotechnology industry”. It also “offers key networking and partnering opportunities” for small biotech companies like Neuronascent.

Dec 14, 2010 - Judith Kelleher-Andersson, Ph.D., the founder and CSO of Neuronascent was an invited speaker at CBI’s 4th Annual Alzheimer’s Disease Drug Discovery Summit. Read more...

Dec 10, 2010 - Neuronascent receives a Maryland Biotechnology Center Translational Research award for their application entitled “Preclinical Development of Novel Neurogenic Depression Candidate." Read more...

Oct 31, 2010 - Neuronascent receives a Therapeutic Drug Discovery Grant awarded to companies that are presently developing therapeutics for diseases with unmet need. Read more...